Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration

  • Regeneron Pharmaceuticals Inc REGN revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related macular degeneration (wet AMD).
  • 43% of wet age-related macular degeneration patients dosed with an 8 mg dose of Eylea reported no retinal fluid after four weeks compared with 26.4% of patients receiving a 2 mg dose of the drug.
  • Regeneron and Bayer AG BAYRY are jointly developing aflibercept 8 mg.
  • The study is part of Regeneron’s ongoing clinical program to expand Eylea’s approved dosing into the 8 mg format. 
  • Regeneron has two Phase 3 studies looking at the 8 mg dose in wet AMD, with early results expected in 1H of 2022.
  • On the safety front, after 16 weeks, 17% of patients receiving the 8 mg dose reported side effects compared with 22.6% on the 2 mg dose. 
  • Two serious ocular side effects were reported, one in the 8 mg cohort and the other in the 2 mg cohort. 
  • There were no instances of intraocular inflammation (including occlusive retinal vasculitis), anti-platelet trialists’ collaboration (APTC)-defined arterial thromboembolic events or deaths in either patient group.
  • Price Action: REGN shares are down 0.40% at $664.63 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralAge-Related Macular DegenerationBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!